1. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study
- Author
-
Mamady Kone, Mahamadoun H. Assadou, Rathy Mohan, Jacquelyn Lane, Jennifer Kwan, John Woodford, Patrick E. Duffy, Justin Doritchamou, Dominic Esposito, Emily Higbee, Alassane Dicko, Kaitlyn Sadtler, Oumar Attaher, Irfan Zaidi, M'Bouye Doucoure, Issaka Sagara, Amatigue Zeguime, Abdoulaye Katile, Malaria Research and Training Center [Bamako, Mali] (MRTC), Université de Bamako, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Malbec, Odile, and Université des sciences, des techniques et des technologies de Bamako (USTTB)
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Mali ,Article ,Herd immunity ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,West Africa ,medicine ,Seroprevalence ,Cumulative incidence ,030212 general & internal medicine ,Prospective cohort study ,030304 developmental biology ,Subclinical infection ,2. Zero hunger ,0303 health sciences ,seroprevalence ,business.industry ,SARS-CoV-2 ,COVID-19 ,Confidence interval ,3. Good health ,[SDV] Life Sciences [q-bio] ,Infectious Diseases ,Serostatus ,business ,Demography - Abstract
BACKGROUND: The extent of SARS-CoV-2 exposure and transmission in Mali and the surrounding region is not well understood, although infection has been confirmed in nearly 14,000 symptomatic individuals and their contacts since the first case in March 2020. We aimed to estimate the cumulative incidence of SARS-CoV-2 in three Malian communities, and understand factors associated with infection. METHODS: Between 27 July 2020 and 29 January 2021, we collected blood samples along with demographic, social, medical and self-reported symptoms information from residents aged 6 months and older in three study communities at two study visits. SARS-CoV-2 antibodies were measured using a highly specific two-antigen ELISA optimized for use in Mali. We calculated cumulative adjusted seroprevalence for each site and evaluated factors associated with serostatus at each visit by univariate and multivariate analysis. FINDINGS: Overall, 94.8% (2533/2672) of participants completed both study visits. A total of 50.3% (1343/2672) of participants were male, and 31.3% (837/2672) were aged
- Published
- 2021